EpiAxis Therapeutics is pleased to announce the appointment of Rob McInnes as a non-executive director to the EpiAxis Board, following a successful fund raise supported by Sydney Angels.

McInnes is one of Australia’s leading biotech IP specialists having initially trained as a protein chemist before turning to commercial law, specialising in intellectual property transactions. He is currently the principal of Rob McInnes IP Advisory, which he founded after practising for 30 years in large law and patent attorney firms.  McInnes advises clients on the management and commercialisation of IP rights, with a focus on planning, negotiating and structuring licence agreements and R&D contracts.

For the past decade Rob has been ranked as Australia’s most highly recommended patent and technology licensing lawyer and is one of the few Australian lawyers to have met the requirements for the US-based Certified Licensing Professional qualification. He is an active Sydney Angels investor and a mentor or expert-in-residence at a number of start-up incubators.

“Rob adds to the depth of knowledge on our Board at a time when we are looking to a dynamic and diversified future,” Dr Fuller said. “EpiAxis now has one of the best credentialed biotech boards in Australia.”

Pictured main: Dr David Fuller and Rob McInnes at the EpiAxis Therapeutics Board Meeting on December 17, 2020.